ALPS stock forecast, quote, news & analysis
ALPS Group Inc is an investment holding company involved in research and development, including stem cell and biotechnology-related business, and investing and managing businesses such as health and beauty centres and medical centres... Show more
Why Alps Group (ALPS) Stock Is Down -18% in the Last 30 Days
Key Takeaways
- Alps Group shares declined roughly 18% over the past 30 days, falling from about $0.40 to around $0.32 as of late October 2026.
- The pullback was driven largely by a proposed 1-for-5 reverse stock split aimed at restoring Nasdaq's $1.00 minimum bid price requirement, signaling listing-compliance pressure.
- Over the last quarter, the stock is down approximately 29%, extending a longer downtrend from its $12.01 52-week high.
- A "Sell (E+)" rating reiterated by Weiss Ratings in early October added to cautious investor sentiment.
- Fundamentally, the company reported fiscal 2026 revenue growth of 44% to $4.9 million, but it remains a pre-profit micro-cap with a market capitalization near $54 million.
- For additional detail on valuation and expectations, explore Alps Group's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see AI-driven trading strategies applied across the market.
Alps Group (ALPS) Company Overview and Market Position
Alps Group Inc is a revenue-generating, integrated biotechnology platform headquartered in Kuala Lumpur, Malaysia, and the parent company of Alps Life Sciences Inc. The company operates across three core areas: cell manufacturing, molecular diagnostics, and clinical delivery. Its portfolio spans cellular therapy programs such as MyImmune natural killer (NK) cells and CAR-T research, mRNA-based vaccine development, diabetes treatments, and induced pluripotent stem cell (iPS) technology, alongside molecular diagnostics through its MyGenome laboratory. Alps Group also provides aesthetics, cosmetic, and general healthcare and wellness services. The company completed a business combination with Globalink Investment Inc. and began trading on the Nasdaq under the symbol ALPS in October 2025.
Alps Group (ALPS) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, Alps Group shares declined approximately 18%, moving from around $0.396 in late September to a closing price of $0.3248 in late October 2026. The move was punctuated by a sharp single-session drop in early October and continued gradual selling pressure into the end of the month.
The quarterly picture is weaker still. Measured from late July, when the stock traded near $0.46, the shares have fallen roughly 29%. This reflects a persistent, multi-month downtrend rather than a short-lived correction, with the stock trading well below its $12.01 52-week high and its market capitalization hovering near $54 million.
What Drove ALPS Stock Price in the Last 30 Days
The dominant catalyst behind the recent decline was the company's proposal of a 1-for-5 reverse stock split, announced in early October and put to a shareholder vote later in the month. The move is designed to lift the share price above Nasdaq's $1.00 minimum bid requirement, which Alps Group previously flagged as a deficiency in May 2026. While a reverse split does not change a company's underlying value, it underscores listing-compliance pressure and raised concerns about potential future share issuance after an associated increase in authorized capital.
Separately, Weiss Ratings reiterated a "Sell (E+)" rating on the stock in early October, reinforcing negative sentiment. As a thinly traded micro-cap, Alps Group is also susceptible to outsized price swings on relatively modest volume, which amplified the October sell-off.
What Drove ALPS Stock Performance Over the Last Quarter
The quarterly decline reflects a broader narrative of regulatory and structural headwinds layered on top of a pre-profit business. The Nasdaq minimum bid price deficiency notice, first disclosed in May 2026, has kept compliance risk front and center for investors, and the subsequent reverse-split proposal formalized the company's response. These factors have weighed on the stock even as the company's operating story improved.
On a fundamental basis, Alps Group reported fiscal 2026 revenue growth of 44% to $4.9 million, led by cellular therapy, medical testing, laboratory services, aesthetics, and healthcare products. However, the company continues to generate net losses, and its negative earnings per share mean the market is valuing the business primarily on growth prospects rather than current profitability.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots drawn from a much larger universe of hundreds of bots trading thousands of tickers. Only the top-performing and most relevant strategies are surfaced in this section, giving users a focused view of active, data-driven approaches. The bots vary widely in strategy, timeframe, and performance metrics, so investors can compare different styles rather than a one-size-fits-all signal. For those seeking to supplement fundamental analysis with systematic, algorithm-driven insight, the page offers a practical starting point to explore how automated strategies are navigating current market conditions.
ALPS Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor the implementation of the reverse stock split and whether it successfully restores Nasdaq listing compliance, as well as any further actions to address the minimum bid price requirement. The company's path to profitability remains a central question, given persistent net losses despite strong revenue growth. Continued expansion across cellular therapy, molecular diagnostics, and aesthetics services will be important to sustaining the growth narrative. Dilution risk from the authorized share increase, the pace of new product and accreditation milestones, and broader sentiment toward small-cap biotechnology stocks are additional factors likely to influence the share price in the months ahead.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ALPS in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 05, 2026
ALPS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 12 of 21 cases where ALPS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 57%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALPS's RSI Oscillator exited the oversold zone, 4 of 11 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 36%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 17 of 47 cases where ALPS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 36%.
The Moving Average Convergence Divergence (MACD) for ALPS just turned positive on November 03, 2026. Looking at past instances where ALPS's MACD turned positive, the stock continued to rise in 21 of 51 cases over the following month. The odds of a continued upward trend are 41%.
Following a +5.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALPS advanced for three days, in 35 of 71 cases, the price rose further within the following month. The odds of a continued upward trend are 49%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALPS as a result. In 21 of 69 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 30%.
ALPS moved below its 50-day moving average on October 07, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ALPS crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 3 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 25%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALPS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for ALPS entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (3.498). P/E Ratio (0.000) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (13.699) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. ALPS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALPS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology